Nova Eye Medical Ltd · ASX:EYE
Nova Eye Medical — Investor Presentation (August 2023)
15 slides from Nova Eye Medical's investor presentation, Aug 28, 2023
Slide 1: Results for the Year ended 30 June 2023
Results for the Year ended 30 June 2023 Nova Eye Medical Limited (ASX:EYE) Strong Financial Results with Record Global Sales August 2023 nova-eye.com | 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any st
Slide 3: FY23 Achievements
FY23 Achievements Strong Financial Results with Record Global Sales Record Substantial lift in Sales in the USA global sales gross margin to Cash on hand 3 months to 31 July 2023 US$11.3m 73% A$7.4m US$2.2m for the glaucoma surgical compared to 60% at 30 June 2023 to up 32% on pcp, driven by devices
Slide 4: New iTrack Advance
4 • New iTrack™ Advance consumable MIGS device is redefining the treatment of glaucoma in its early stages. • Canaloplasty offers a stent-free, tissue-preserving surgical treatment for glaucoma. • Enhanced version of our original iTrack™ microcatheter, which was first brought to market in 2008 and h
Slide 5: USA Sales Growth Plan, iTrack Advance
USA Sales Growth Plan, A Active Accounts, Glaucoma (x200) B Inactive Accounts, Glaucoma (x300) iTrack™ Advance Current Sales Growth C New Accounts, Glaucoma (x900) 32% FY23 Active Accounts, Glaucoma | x200 surgeons A Successfully transitioned existing iTrack™ customer accounts to iTrack™ Advance dur
Slide 6: Our Glaucoma opportunity
Our Glaucoma opportunity • The glaucoma consumable surgical devices market is the fastest growing segment of the ophthalmic market. 156.2 million • The aging global population drives prevalence, People worldwide with Glaucoma 1 representing a significant opportunity for our global business. • Signif
Slide 7: Important FY23 Activities
Important FY23 Activities Record global sales revenue of US$11.3 million for Equates to sales revenue of A$16.7million, the glaucoma surgical device segment during the up 26% on the prior comparable period. period, up 18% on the prior comparable period. In the USA, sales were achieved late in the se
Slide 8: Clinical Data Update: Real-World Registry Data
Clinical Data Update Real-World Registry Data Reinforces Safety and Efficacy of iTrackTM Summary of the Real-World Registry so far: Continued to invest in clinical data program to support market development and market access • 367 patients of a broad range of ethnicities. initiatives, including: • 2
Slide 9: FY23 Glaucoma Operating Result
FY23 Glaucoma Operating Result US $'000’s¹ US $'000’s1 H1FY23 H2FY23 Geographic Sales Composition: (July 2022 (Jan 2023 FY22 FY23 • Sales composition US$: to Dec to June 2022) 2023) • USA 59% (pcp 67%) • W Europe 25% (pcp 28%) 6,359 Sales USA 3,084 3,564 6,648 • China 16% (pcp 5%) • Large contributi
Slide 10: AlphaRET for RETINAL DISEASE
AlphaRET for RETINAL DISEASE • Age-related macular degeneration (AMD) is the leading cause of blindness in industrialised countries in people over the age of 50 years. • Late-stage Wet AMD market is currently the only market served (drug 2RT® is a proprietary, world-first therapy anti-VEGF injection
Slide 11: FY23 Group Cash
FY23 Group Cash A$'000’s H1FY23 H2FY23 (July 2022 to (Jan 2023 to FY23 • Material improvement in cash Dec 2022) June 2023) out flow from operations in the second half due to Receipts from customers 8,613 8,968 17,581 • Increased selling prices • Production improvements in Fremont Payments to supplie
Slide 12: Nova Eye Group Outlook
Nova Eye Group Outlook Sales of new iTrack™ Advance in the USA are expected to drive significant sales growth for the Company’s glaucoma surgical device segment in the 2024 financial year and beyond. Operating expenditure will increase to support the expansion of global sales in the glaucoma surgica
Slide 13: Business Snapshot
Business Snapshot Nova Eye Medical leads the way in interventional treatment solutions for glaucoma and age-related macular degeneration (AMD), the leading causes of blindness in the developed world. Nova Eye Medical, Glaucoma AlphaRET, AMD Develop, market and sell comprehensive portfolio Commercial
Slide 14: Company Overview
Company Overview Capital Structure Share Price Chart 6,000,000 $0.35 ASX Code EYE Share Price (at 21 August 2023) $0.25 5,000,000 $0.30 Shares on Issue 190 M 4,000,000 $0.25 Unlisted Options 3.35 M 3,000,000 Market Capitalisation $49.5 M $0.20 2,000,000 Cash $7.54M $0.15 1,000,000 Top 20 Shareholder
Slide 15: Tom Spurling, Kate Hunt, Mark Flynn
Tom Spurling Kate Hunt Mark Flynn Managing Director Chief Commercial Officer Investor Relations +61 8 8362 0193 +61 404 080 679 +61 416 068 733 tspurling@nova-eye.com khunt@nova-eye.com mflynn@nova-eye.com nova-eye.com | 15
Nova Eye Medical — Investor Presentation (August 2023) on 6ix